Stocks / NASDAQ / Tempest Therapeutics Inc.

Tempest Therapeutics Inc.

Our Opinion

Tempest Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of its medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“In extensive animal studies, TPST-1120 therapy used as a single agent or in combination with other anti-cancer drugs resulted in significant reductions in tumor growth and stimulation of durable anti-tumor immunity.” Read the following article

Company Description

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.

Company Website: https://www.tempesttx.com